spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cutaneous T-cell lymphoma 

 HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Apr 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2020
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 16 Sep 2019
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2019
Soligenix Appoints Jonathan Guarino as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2018
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Nov 2016
miRagen Therapeutics and Signal Genetics Sign Merger Agreement
Diagnostics Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Sep 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Aug 2015
Soligenix Enters into a $10 Million Equity Purchase Agreement
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2014
OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2013
Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 15 Oct 2012
The Gores Group Extends Binding Offer to Acquire Therakos, Inc. from Ortho-Clinical Diagnostics, Inc.
Devices Oncology Mergers & Acquisitions Personnel
 HSMN NewsFeed - 5 Jun 2012
Ceptaris Secures $10 Million in Series D-1 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Feb 2012
Ceptaris Secures $15M in Venture Debt Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Jan 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jan 2012
Yaupon Changes Name to Ceptaris Therapeutics, Inc.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Aug 2011
Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Jul 2011
Yaupon Therapeutics, Inc. Appoints New Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 May 2011
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jan 2010
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Jan 2010
BioCryst's Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Dec 2009
Celgene to Acquire Gloucester Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2009
U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
Devices Oncology FDA
 HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 18 Jun 2008
William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Apr 2008
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Mar 2008
Biologics, Dermal Fillers are Key to Dermatological Drug Market Growth
Devices Biopharmaceuticals Dermatology
 HSMN NewsFeed - 28 Jan 2008
Gloucester Pharmaceuticals Announces New Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
BioCryst Provides Forodesine HCl Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
Yaupon Therapeutics Closes $14.5 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Nov 2007
Marketing Application for Vorinostat Filed in Europe for the Treatment of Advanced, Refractory Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Oct 2007
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2007
Genmab Regains Rights to HuMax-CD4
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
Cyclacel Pharmaceuticals Announces Appointment of Distinguished Pharma Executive as Senior Vice President, Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jun 2007
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2007
Favrille Appoints Richard Ghalie, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2007
Gloucester Pharmaceuticals Appoints Pharmaceutical Veteran, Donald Hayden, as Vice-Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
EMEA Grants Orphan Drug Designation to BioCryst's Fodosine(TM) for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Jan 2007
Gloucester Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase II Trial of Romidepsin in Patients with Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2007
BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial in Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Results of Clinical Trial Program Suggest Fodosine(TM) Demonstrates Clinical Activity in Certain Types of Leukemia and Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2006
BioCryst's Fodosine(TM) Granted Orphan Status In Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Nov 2006
Yaupon Therapeutics Closes $4 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Nov 2006
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2006
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jul 2006
Favrille Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity of Lead Product Candidate FavId in Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2006
Gloucester Pharmaceuticals Appoints Jean C. Nichols, Ph.D., Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 38

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 38 additional stories matching:
cutaneous T-cell lymphoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.